Abstract
Objectives The role of intraperitoneal (IP) chemotherapy in the management of advanced ovarian cancer has been controversial. We aimed to compare survival outcomes associated with IP vs intravenous (IV) chemotherapy. Methods We reviewed the long-term survival records of 271 women with stage IIIC or IV high-grade serous ovarian cancer treated with primary cytoreductive surgery (PCS) followed by IP or intravenous (IV) chemotherapy between 2001–2015 with a minimum follow-up of 4 years. 5-year progression free (PFS) and overall survival (OS) rates were compared using Kaplan-Meier survival analysis and covariates were evaluated using Cox regression analysis. Results Women who received IP chemotherapy after PCS (n=91) were more likely to have undergone aggressive surgery (p Conclusions IP chemotherapy showed a trend towards improved survival over conventional IV chemotherapy, especially in patients with no residual disease.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
